Adverse effects of recombinant human insulin-like growth factor I in obese insulin-resistant type II diabetic patients.

Jabri N, Schalch DS, Schwartz SL, Fischer JS, Kipnes MS, Radnik BJ, Turman NJ, Marcsisin VS, Guler HP

Diabetes1 Mar 1994Cited by 63 (Europe PMC)

PMID8314009DOI10.2337/diab.43.3.369PepBankPUB-08314009

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study13

13 results from studies that gave the peptide. 13 results from people.

01HumanNon-randomized trialEfficacy outcome
In obese diabetic patients, glucose control with rhIGF-I was comparable or enhanced in four patients and diminished in three versus NPH insulin.
In plain wordsIn obese diabetic patients, glucose control with rhIGF-I was comparable or better in four and worse in three versus prior NPH insulin.
Peptide
IGF-1 (mecasermin)
Outcome
MixedBlood glucose control
Study
n = 7
Comparator
Twice daily NPH insulin
Outcome group
Glycemic control · Metabolic and weight
Studied dose
120 and 160 micrograms/kg twice daily · subcutaneous · 4-52 daysAs given in this study (human).
Measurements
Patients with comparable or enhanced glucose control
4 patients
rhIGF-I vs NPH insulin control period
Patients with diminished glucose control
3 patients
rhIGF-I vs NPH insulin control period
Source sentences
Summary
Four patients exhibited comparable or enhanced, whereas three had diminished, blood glucose control on rhIGF-I relative to that while on twice daily NPH insulin during the six-week control period.
1 context sentence(design, population, supporting numbers)
Summary · context
To assess the efficacy of recombinant human IGF-I in subjects with the most common form of insulin resistance, e.g., obese, type II diabetic patients, we administered recombinant human IGF-I (rhIGF) in doses of 120 and 160 micrograms/kg twice daily for 4-52 days to seven such individuals
Report a problemFND-0831400901
02HumanNon-randomized trialSafety outcome
All seven obese diabetic patients discontinued rhIGF-I because of adverse effects.
In plain wordsAll seven obese diabetic patients stopped rhIGF-I because of side effects.
Peptide
IGF-1 (mecasermin)
Outcome
Not applicableTreatment discontinuation
Study
n = 7
Outcome group
Adverse events · Whole body
Studied dose
120 and 160 micrograms/kg twice daily · subcutaneous · 4-52 daysAs given in this study (human).
Source sentences
Summary
The occurrence of adverse effects in all patients compelled us to discontinue rhIGF-I administration before completing the 8-week treatment period.
1 context sentence(design, population, supporting numbers)
Summary · context
To assess the efficacy of recombinant human IGF-I in subjects with the most common form of insulin resistance, e.g., obese, type II diabetic patients, we administered recombinant human IGF-I (rhIGF) in doses of 120 and 160 micrograms/kg twice daily for 4-52 days to seven such individuals
Report a problemFND-0831400902
03HumanNon-randomized trialSafety outcome
Obese diabetic patients experienced facial and hand edema during rhIGF-I treatment.
In plain wordsObese diabetic patients developed swelling of the face and hands during rhIGF-I treatment.
Peptide
IGF-1 (mecasermin)
Outcome
Not applicableEdema
Study
n = 7
Outcome group
Adverse events · Whole body
Studied dose
120 and 160 micrograms/kg twice daily · subcutaneous · 4-52 daysAs given in this study (human).
Source sentences
Summary
These adverse effects included edema primarily on the face and hands, mild weight gain, occasional dyspnea, bilateral jaw tenderness, arthralgias and myalgias, fatigue, tachycardia, flushing, orthostatic hypotension, and local burning at the injection site.
1 context sentence(design, population, supporting numbers)
Summary · context
To assess the efficacy of recombinant human IGF-I in subjects with the most common form of insulin resistance, e.g., obese, type II diabetic patients, we administered recombinant human IGF-I (rhIGF) in doses of 120 and 160 micrograms/kg twice daily for 4-52 days to seven such individuals
Report a problemFND-0831400903
04HumanNon-randomized trialSafety outcome
Obese diabetic patients experienced mild weight gain during rhIGF-I treatment.
In plain wordsObese diabetic patients gained some weight during rhIGF-I treatment.
Peptide
IGF-1 (mecasermin)
Outcome
IncreaseWeight gain
Study
n = 7
Outcome group
Body weight · Metabolic and weight
Studied dose
120 and 160 micrograms/kg twice daily · subcutaneous · 4-52 daysAs given in this study (human).
Source sentences
Summary
These adverse effects included edema primarily on the face and hands, mild weight gain, occasional dyspnea, bilateral jaw tenderness, arthralgias and myalgias, fatigue, tachycardia, flushing, orthostatic hypotension, and local burning at the injection site.
1 context sentence(design, population, supporting numbers)
Summary · context
To assess the efficacy of recombinant human IGF-I in subjects with the most common form of insulin resistance, e.g., obese, type II diabetic patients, we administered recombinant human IGF-I (rhIGF) in doses of 120 and 160 micrograms/kg twice daily for 4-52 days to seven such individuals
Report a problemFND-0831400904
05HumanNon-randomized trialSafety outcome
Obese diabetic patients experienced occasional dyspnea during rhIGF-I treatment.
In plain wordsObese diabetic patients sometimes had difficulty breathing during rhIGF-I treatment.
Peptide
IGF-1 (mecasermin)
Outcome
Not applicableDyspnea
Study
n = 7
Outcome group
Adverse events · Respiratory
Studied dose
120 and 160 micrograms/kg twice daily · subcutaneous · 4-52 daysAs given in this study (human).
Source sentences
Summary
These adverse effects included edema primarily on the face and hands, mild weight gain, occasional dyspnea, bilateral jaw tenderness, arthralgias and myalgias, fatigue, tachycardia, flushing, orthostatic hypotension, and local burning at the injection site.
1 context sentence(design, population, supporting numbers)
Summary · context
To assess the efficacy of recombinant human IGF-I in subjects with the most common form of insulin resistance, e.g., obese, type II diabetic patients, we administered recombinant human IGF-I (rhIGF) in doses of 120 and 160 micrograms/kg twice daily for 4-52 days to seven such individuals
Report a problemFND-0831400905
06HumanNon-randomized trialSafety outcome
Obese diabetic patients experienced bilateral jaw tenderness during rhIGF-I treatment.
In plain wordsObese diabetic patients had tenderness on both sides of the jaw during rhIGF-I treatment.
Peptide
IGF-1 (mecasermin)
Outcome
Not applicableJaw tenderness
Study
n = 7
Outcome group
Adverse events · Musculoskeletal
Studied dose
120 and 160 micrograms/kg twice daily · subcutaneous · 4-52 daysAs given in this study (human).
Source sentences
Summary
These adverse effects included edema primarily on the face and hands, mild weight gain, occasional dyspnea, bilateral jaw tenderness, arthralgias and myalgias, fatigue, tachycardia, flushing, orthostatic hypotension, and local burning at the injection site.
1 context sentence(design, population, supporting numbers)
Summary · context
To assess the efficacy of recombinant human IGF-I in subjects with the most common form of insulin resistance, e.g., obese, type II diabetic patients, we administered recombinant human IGF-I (rhIGF) in doses of 120 and 160 micrograms/kg twice daily for 4-52 days to seven such individuals
Report a problemFND-0831400906
07HumanNon-randomized trialSafety outcome
Obese diabetic patients experienced arthralgias during rhIGF-I treatment.
In plain wordsObese diabetic patients had joint pain during rhIGF-I treatment.
Peptide
IGF-1 (mecasermin)
Outcome
Not applicableArthralgias
Study
n = 7
Outcome group
Pain · Musculoskeletal
Studied dose
120 and 160 micrograms/kg twice daily · subcutaneous · 4-52 daysAs given in this study (human).
Source sentences
Summary
These adverse effects included edema primarily on the face and hands, mild weight gain, occasional dyspnea, bilateral jaw tenderness, arthralgias and myalgias, fatigue, tachycardia, flushing, orthostatic hypotension, and local burning at the injection site.
1 context sentence(design, population, supporting numbers)
Summary · context
To assess the efficacy of recombinant human IGF-I in subjects with the most common form of insulin resistance, e.g., obese, type II diabetic patients, we administered recombinant human IGF-I (rhIGF) in doses of 120 and 160 micrograms/kg twice daily for 4-52 days to seven such individuals
Report a problemFND-0831400907
08HumanNon-randomized trialSafety outcome
Obese diabetic patients experienced myalgias during rhIGF-I treatment.
In plain wordsObese diabetic patients had muscle pain during rhIGF-I treatment.
Peptide
IGF-1 (mecasermin)
Outcome
Not applicableMyalgias
Study
n = 7
Outcome group
Pain · Musculoskeletal
Studied dose
120 and 160 micrograms/kg twice daily · subcutaneous · 4-52 daysAs given in this study (human).
Source sentences
Summary
These adverse effects included edema primarily on the face and hands, mild weight gain, occasional dyspnea, bilateral jaw tenderness, arthralgias and myalgias, fatigue, tachycardia, flushing, orthostatic hypotension, and local burning at the injection site.
1 context sentence(design, population, supporting numbers)
Summary · context
To assess the efficacy of recombinant human IGF-I in subjects with the most common form of insulin resistance, e.g., obese, type II diabetic patients, we administered recombinant human IGF-I (rhIGF) in doses of 120 and 160 micrograms/kg twice daily for 4-52 days to seven such individuals
Report a problemFND-0831400908
09HumanNon-randomized trialSafety outcome
Obese diabetic patients experienced fatigue during rhIGF-I treatment.
In plain wordsObese diabetic patients felt tired during rhIGF-I treatment.
Peptide
IGF-1 (mecasermin)
Outcome
Not applicableFatigue
Study
n = 7
Outcome group
Adverse events · Whole body
Studied dose
120 and 160 micrograms/kg twice daily · subcutaneous · 4-52 daysAs given in this study (human).
Source sentences
Summary
These adverse effects included edema primarily on the face and hands, mild weight gain, occasional dyspnea, bilateral jaw tenderness, arthralgias and myalgias, fatigue, tachycardia, flushing, orthostatic hypotension, and local burning at the injection site.
1 context sentence(design, population, supporting numbers)
Summary · context
To assess the efficacy of recombinant human IGF-I in subjects with the most common form of insulin resistance, e.g., obese, type II diabetic patients, we administered recombinant human IGF-I (rhIGF) in doses of 120 and 160 micrograms/kg twice daily for 4-52 days to seven such individuals
Report a problemFND-0831400909
10HumanNon-randomized trialSafety outcome
Obese diabetic patients experienced tachycardia during rhIGF-I treatment.
In plain wordsObese diabetic patients had a fast heartbeat during rhIGF-I treatment.
Peptide
IGF-1 (mecasermin)
Outcome
Not applicableTachycardia
Study
n = 7
Outcome group
Adverse events · Cardiovascular
Studied dose
120 and 160 micrograms/kg twice daily · subcutaneous · 4-52 daysAs given in this study (human).
Source sentences
Summary
These adverse effects included edema primarily on the face and hands, mild weight gain, occasional dyspnea, bilateral jaw tenderness, arthralgias and myalgias, fatigue, tachycardia, flushing, orthostatic hypotension, and local burning at the injection site.
1 context sentence(design, population, supporting numbers)
Summary · context
To assess the efficacy of recombinant human IGF-I in subjects with the most common form of insulin resistance, e.g., obese, type II diabetic patients, we administered recombinant human IGF-I (rhIGF) in doses of 120 and 160 micrograms/kg twice daily for 4-52 days to seven such individuals
Report a problemFND-0831400910
11HumanNon-randomized trialSafety outcome
Obese diabetic patients experienced flushing during rhIGF-I treatment.
In plain wordsObese diabetic patients developed flushing during rhIGF-I treatment.
Peptide
IGF-1 (mecasermin)
Outcome
Not applicableFlushing
Study
n = 7
Outcome group
Adverse events · Skin and wound
Studied dose
120 and 160 micrograms/kg twice daily · subcutaneous · 4-52 daysAs given in this study (human).
Source sentences
Summary
These adverse effects included edema primarily on the face and hands, mild weight gain, occasional dyspnea, bilateral jaw tenderness, arthralgias and myalgias, fatigue, tachycardia, flushing, orthostatic hypotension, and local burning at the injection site.
1 context sentence(design, population, supporting numbers)
Summary · context
To assess the efficacy of recombinant human IGF-I in subjects with the most common form of insulin resistance, e.g., obese, type II diabetic patients, we administered recombinant human IGF-I (rhIGF) in doses of 120 and 160 micrograms/kg twice daily for 4-52 days to seven such individuals
Report a problemFND-0831400911
12HumanNon-randomized trialSafety outcome
Obese diabetic patients experienced orthostatic hypotension during rhIGF-I treatment.
In plain wordsObese diabetic patients had low blood pressure when standing during rhIGF-I treatment.
Peptide
IGF-1 (mecasermin)
Outcome
Not applicableOrthostatic hypotension
Study
n = 7
Outcome group
Blood pressure · Cardiovascular
Studied dose
120 and 160 micrograms/kg twice daily · subcutaneous · 4-52 daysAs given in this study (human).
Source sentences
Summary
These adverse effects included edema primarily on the face and hands, mild weight gain, occasional dyspnea, bilateral jaw tenderness, arthralgias and myalgias, fatigue, tachycardia, flushing, orthostatic hypotension, and local burning at the injection site.
1 context sentence(design, population, supporting numbers)
Summary · context
To assess the efficacy of recombinant human IGF-I in subjects with the most common form of insulin resistance, e.g., obese, type II diabetic patients, we administered recombinant human IGF-I (rhIGF) in doses of 120 and 160 micrograms/kg twice daily for 4-52 days to seven such individuals
Report a problemFND-0831400912
13HumanNon-randomized trialSafety outcome
Obese diabetic patients experienced local injection-site burning during rhIGF-I treatment.
In plain wordsObese diabetic patients felt burning at the injection site during rhIGF-I treatment.
Peptide
IGF-1 (mecasermin)
Outcome
Not applicableInjection-site burning
Study
n = 7
Outcome group
Adverse events · Skin and wound
Studied dose
120 and 160 micrograms/kg twice daily · subcutaneous · 4-52 daysAs given in this study (human).
Source sentences
Summary
These adverse effects included edema primarily on the face and hands, mild weight gain, occasional dyspnea, bilateral jaw tenderness, arthralgias and myalgias, fatigue, tachycardia, flushing, orthostatic hypotension, and local burning at the injection site.
1 context sentence(design, population, supporting numbers)
Summary · context
To assess the efficacy of recombinant human IGF-I in subjects with the most common form of insulin resistance, e.g., obese, type II diabetic patients, we administered recombinant human IGF-I (rhIGF) in doses of 120 and 160 micrograms/kg twice daily for 4-52 days to seven such individuals
Report a problemFND-0831400913

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
14 Oct 2026, 05:02 UTC
Study results updated
Version 1
14 Oct 2026, 01:46 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.